These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32176062)

  • 61. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading.
    Ghaderi B; Moghbel H; Daneshkhah N; Babahajian A; Sheikhesmaeili F
    J Gastrointest Cancer; 2019 Sep; 50(3):525-529. PubMed ID: 29806060
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tumor Abnormal Protein in the Diagnosis of Breast Cancer in Patients with a Palpable Mass.
    Chen WX; Yang LG; Cheng L; Zhu YL
    Ann Clin Lab Sci; 2019 May; 49(3):297-301. PubMed ID: 31308027
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical value of preoperative CA19-9 levels in evaluating resectability of gallbladder carcinoma.
    Liu F; Wang JK; Ma WJ; Yang Q; Hu HJ; Li FY
    ANZ J Surg; 2019 Mar; 89(3):E76-E80. PubMed ID: 30306702
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer.
    Yu Y; Tong Y; Zhong A; Wang Y; Lu R; Guo L
    Medicine (Baltimore); 2020 Dec; 99(52):e23863. PubMed ID: 33350781
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.
    Jia F; Liu M; Li X; Zhang F; Yue S; Liu J
    World J Surg Oncol; 2019 Sep; 17(1):163. PubMed ID: 31526392
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm.
    Aronsson L; Andersson R; Bauden M; Andersson B; Bygott T; Ansari D
    Scand J Gastroenterol; 2018 Dec; 53(12):1597-1603. PubMed ID: 30509115
    [TBL] [Abstract][Full Text] [Related]  

  • 68. TNM staging for GIT cancers is correlated with the level of MMPs and TGF-β1.
    El-Ashmawy NE; Khedr NF; Mansour MG; Al-Ashmawy GM
    Clin Exp Med; 2020 Nov; 20(4):545-555. PubMed ID: 32772210
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Role of serum Metadherin mRNA expression in the diagnosis and prediction of survival in patients with colorectal cancer.
    Abdel Ghafar MT; Gharib F; Abdel-Salam S; Elkhouly RA; Elshora A; Shalaby KH; El-Guindy D; El-Rashidy MA; Soliman NA; Abu-Elenin MM; Allam AA
    Mol Biol Rep; 2020 Apr; 47(4):2509-2519. PubMed ID: 32088817
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
    Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
    Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.
    Cetin S; Dede I
    J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.
    Liu L; Xu H; Wang W; Wu C; Chen Y; Yang J; Cen P; Xu J; Liu C; Long J; Guha S; Fu D; Ni Q; Jatoi A; Chari S; McCleary-Wheeler AL; Fernandez-Zapico ME; Li M; Yu X
    Int J Cancer; 2015 May; 136(9):2216-27. PubMed ID: 25273947
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Urinary gonadotropin peptide in patients with cancer of digestive organs.
    Motoo Y; Watanabe H; Yamaguchi Y; Mouri I; Fujii T; Yamakawa O; Satomura Y; Okai T; Sawabu N
    Anticancer Res; 1996; 16(4A):2041-8. PubMed ID: 8712740
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT; Brünner N; De Muckadell OB
    Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 79. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Changes and Clinical Significance of Preoperative and Postoperative Serum CEA and CA19-9 in Gastric Cancer.
    Jing R; Cui M; Ju S; Pan S
    Clin Lab; 2020 Apr; 66(4):. PubMed ID: 32255307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.